Heerlen, NL, 06 Jun 2012 09:15 CEST
Royal DSM (NYSE Euronext: DSM KON), the global Life Sciences and Materials Sciences company, announced today the expiration of the mandatory waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, for its previously announced tender offer for all outstanding shares of common stock of Kensey Nash Corporation (NASDAQ: KNSY) at a price of $38.50 per share (the “Offer”). This condition of the Offer is thus satisfied.
The Offer remains subject to the satisfaction of certain other conditions. The Offer is scheduled to expire at 12:00 midnight (New York City time) at the end of Monday, June 18, 2012, unless the Offer is extended.
Kensey Nash is a medical device company primarily focused on regenerative medicine utilizing its proprietary collagen and synthetic polymer technology. The company is recognized as a leader for innovative product development and unique technology in the field of resorbable biomaterials. The company has an extensive range of products, which are sold through strategic partners in multiple medical markets, including the cardiology, orthopedic, sports medicine, spine, trauma, craniomaxillofacial and general surgery markets.